查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1980761

2026-2034年全球出血性疾病治療市場規模、佔有率、趨勢和成長分析報告

Global Bleeding Disorder Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 121 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計出血性疾病治療市場規模將從 2025 年的 228.6 億美元成長到 2034 年的 449.1 億美元，2026 年至 2034 年的複合年成長率為 7.79%。

隨著全球對出血性疾病（BGM）的認知和診斷水準不斷提高，全球出血性疾病市場正穩步成長。出血性疾病，包括血友病和血管性血友病，需要專門的治療來預防過度出血和控制併發症。確診患者數量的增加以及醫療服務可近性的提高，都促使人們對有效的治療方案的需求日益成長。

生物技術和藥物研發的進步顯著推動了市場擴張。重組凝血因子、基因療法和緩釋藥物等創新療法正在改善患者預後並減少治療頻率。醫療機構和病患權益組織也努力提高大眾對出血性疾病的認知，促進早期診斷和更有效的疾病管理。

展望未來，隨著先進治療方法的持續研發，全球出血性疾病治療市場預計將持續成長。基因療法和個人化醫療的發展為更有效、更永續的治療方法創造了新的機會。隨著醫療體系診斷能力的提升和治療可近性的提高，出血性疾病治療市場預計將穩定擴張。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球出血性疾病治療市場：依類型分類

  • 市場分析、洞察與預測
  • A型血友病A
  • B型血友病
  • 血管性血友病
  • 其他

第5章 全球出血性疾病治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • 血漿衍生凝血因子濃縮物
  • 重組凝血因子濃縮物
  • 去氨加壓素
  • 抗纖溶藥物
  • 纖維蛋白膠
  • 其他

第6章 全球出血性疾病治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Shire Plc
    • Baxalta
    • Bayer AG
    • Biogen Inc
    • CSL Behring
    • Novo Nordisk
    • Pfizer Inc
    • Grifols SA
    • Octapharma AG
    • Sanofi SA
    • Alnylam Pharmaceuticals Inc
簡介目錄
Product Code: VMR112115274

The Bleeding Disorder Treatment Market size is expected to reach USD 44.91 Billion in 2034 from USD 22.86 Billion (2025) growing at a CAGR of 7.79% during 2026-2034.

The Global Bleeding Disorder Treatment Market is experiencing steady growth as awareness and diagnosis of bleeding disorders continue to improve worldwide. Bleeding disorders, including hemophilia and von Willebrand disease, require specialized treatments to prevent excessive bleeding and manage complications. The increasing number of diagnosed patients and improved access to healthcare services are contributing to the growing demand for effective treatment options.

Advancements in biotechnology and pharmaceutical development are playing a significant role in market expansion. Innovative therapies such as recombinant clotting factors, gene therapy, and long-acting treatments are improving patient outcomes and reducing the frequency of treatment administration. Healthcare organizations and patient advocacy groups are also working to raise awareness about bleeding disorders, encouraging early diagnosis and better disease management.

Looking forward, the Global Bleeding Disorder Treatment Market is expected to grow due to continued research in advanced therapeutic approaches. The development of gene-based therapies and personalized medicine is creating new opportunities for more effective and long-lasting treatments. As healthcare systems improve diagnostic capabilities and treatment accessibility, the market for bleeding disorder therapies is anticipated to expand steadily.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

By Drug Class

  • Plasma-Derived Coagulation Factor Concentrates
  • Recombinant Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytics
  • Fibrin Sealants
  • Others

COMPANIES PROFILED

  • Takeda Pharmaceutical Company Limited, , Shire Plc, Baxalta, Bayer AG, Biogen Inc, CSL Behring, Novo Nordisk, Pfizer Inc, Grifols SA, Octapharma AG, Sanofi SA, Alnylam Pharmaceuticals Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL BLEEDING DISORDER TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Hemophilia A Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Hemophilia B Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Von Willebrand Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BLEEDING DISORDER TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Drug Class
  • 5.2. Plasma-Derived Coagulation Factor Concentrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Recombinant Coagulation Factor Concentrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Desmopressin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Antifibrinolytics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Fibrin Sealants Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BLEEDING DISORDER TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Type
    • 6.2.2 By Drug Class
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Type
    • 6.3.2 By Drug Class
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Type
    • 6.4.2 By Drug Class
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Type
    • 6.5.2 By Drug Class
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Type
    • 6.6.2 By Drug Class
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL BLEEDING DISORDER TREATMENT INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Shire Plc
    • 8.2.2 Baxalta
    • 8.2.3 Bayer AG
    • 8.2.4 Biogen Inc
    • 8.2.5 CSL Behring
    • 8.2.6 Novo Nordisk
    • 8.2.7 Pfizer Inc
    • 8.2.8 Grifols SA
    • 8.2.9 Octapharma AG
    • 8.2.10 Sanofi S.A
    • 8.2.11 Alnylam Pharmaceuticals Inc